Company / Capital Expenditures
Cartesian Therapeutics, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$9.1M
FY2025
5-year range
$47.0K / $9.1M
FY2021-FY2025
Trend
+4314.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures changed +4314% YoY in FY2025, a notable deviation from the 7-year average annual change of +864%.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of +59.4%.
Improved from $1M to $9M over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +123.5%
- 5-Year CAGR
- +59.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +59.4%, indicating consistent growth.
- In FY2025, capital expenditures increased 4314.1% year-over-year.
- Lowest capital expenditures in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.1M | +4314.1% |
| FY2024 | $206.0K | -81.0% |
| FY2023 | $1.1M | +33.1% |
| FY2022 | $815.0K | +1634.0% |
| FY2021 | $47.0K | -94.7% |
| FY2020 | $884.0K | +20.6% |
| FY2019 | $733.0K | +222.9% |
| FY2016 | $227.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026